Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Market: Market:

Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India BusinessWire - Tue Apr 13, 1:03AM CDT
CMTX - Tue Apr 13, 1:03AM CDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the permission from the Drug Controller General of India (DCGI) to import the...

RDY : 65.01 (+1.37%)
Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market BusinessWire - Wed Apr 7, 3:56AM CDT
CMTX - Wed Apr 7, 3:56AM CDT

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Sapropterin Dihydrochloride...

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY ACCESSWIRE - Tue Mar 9, 10:54PM CST
CMTX - Tue Mar 9, 10:54PM CST

NEW YORK, NY / ACCESSWIRE / March 9, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such investors...

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY Newsfile Corp - Sun Mar 7, 4:41PM CST
CMTX - Sun Mar 7, 4:41PM CST

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited("Dr. Reddy's" or the "Company") (NYSE: RDY). Such...

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire - PRF - Wed Mar 3, 2:00AM CST
CMTX - Wed Mar 3, 2:00AM CST

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact...

RDY : 65.01 (+1.37%)
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid Zacks - Fri Feb 26, 8:47AM CST
Zacks Equity Research - ZACKS - Fri Feb 26, 8:47AM CST

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

TEVA : 10.75 (-0.74%)
RDY : 65.01 (+1.37%)
AMRN : 5.02 (+0.20%)
SAVA : 34.85 (-0.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY Newsfile Corp - Mon Feb 22, 12:17PM CST
CMTX - Mon Feb 22, 12:17PM CST

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited("Dr. Reddy's" or the "Company") (NYSE: RDY)....

RDY : 65.01 (+1.37%)
Dr. Reddy's Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market BusinessWire - Mon Feb 22, 12:13AM CST
CMTX - Mon Feb 22, 12:13AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Lansoprazole DR Orally...

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY ACCESSWIRE - Sat Feb 20, 5:45PM CST
CMTX - Sat Feb 20, 5:45PM CST

NEW YORK, NY / ACCESSWIRE / February 20, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such investors...

RDY : 65.01 (+1.37%)
Dr. Reddy's Initiates Process for Emergency Use Authorization of Sputnik V BusinessWire - Fri Feb 19, 4:45AM CST
CMTX - Fri Feb 19, 4:45AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced that it has initiated the process...

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire - PRF - Thu Feb 18, 11:35PM CST
CMTX - Thu Feb 18, 11:35PM CST

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact...

RDY : 65.01 (+1.37%)
Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market BusinessWire - Thu Feb 18, 12:50AM CST
CMTX - Thu Feb 18, 12:50AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fluphenazine Hydrochloride...

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY Newsfile Corp - Mon Feb 15, 6:38PM CST
CMTX - Mon Feb 15, 6:38PM CST

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited("Dr. Reddy's" or the "Company") (NYSE: RDY)....

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY ACCESSWIRE - Sat Feb 13, 3:50PM CST
CMTX - Sat Feb 13, 3:50PM CST

NEW YORK, NY / ACCESSWIRE / February 13, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such investors...

RDY : 65.01 (+1.37%)
Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market BusinessWire - Tue Feb 2, 3:20AM CST
CMTX - Tue Feb 2, 3:20AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Vigabatrin Tablets...

RDY : 65.01 (+1.37%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire - PRF - Mon Feb 1, 11:18PM CST
CMTX - Mon Feb 1, 11:18PM CST

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact...

RDY : 65.01 (+1.37%)
Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase Zacks - Mon Feb 1, 9:25AM CST
Zacks Equity Research - ZACKS - Mon Feb 1, 9:25AM CST

Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.

ALXN : 163.68 (+3.90%)
RDY : 65.01 (+1.37%)
ACOR : 4.19 (+6.62%)
AVXL : 11.80 (-2.64%)
Dr. Reddy's Q3 & 9M FY21 Financial Results BusinessWire - Fri Jan 29, 3:37AM CST
CMTX - Fri Jan 29, 3:37AM CST

Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and the nine months ended December 31, 2020....

RDY : 65.01 (+1.37%)
Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19 Zacks - Thu Jan 28, 9:10AM CST
Zacks Equity Research - ZACKS - Thu Jan 28, 9:10AM CST

Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.

REGN : 502.60 (+1.61%)
RDY : 65.01 (+1.37%)
MRNA : 170.81 (+6.84%)
LLY : 189.25 (+1.79%)
Dr. Reddy's and GRA Announce Clinically Meaningful Data from Avigan Pivotal Studies PR Newswire Europe - Wed Jan 27, 2:04PM CST
CMTX - Wed Jan 27, 2:04PM CST

Sub-group analysis shows three-day earlier discharge from hospital in low-risk patients hospitalized with COVID-19

RDY : 65.01 (+1.37%)
Please wait...

Barchart Exclusives

The Wheat Bull Remains Intact At The Start Of The 2021 Crop Year Barchart - Thu Apr 15, 10:39AM CDT
CBOT wheat futures are heading into the new crop year at the highest price in years. As the demand side of wheat’s fundamental equation is ever-increasing, consumers worldwide hope that 2021 is another year of bumper crops. Any supply issues could launch the wheat price even higher over the coming months. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
Reserve Your Spot